Search results
Regeneron (NASDAQ: REGN) is a leading biotechnology company using the power of science to bring new medicines to patients in need. Learn more.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.
4 days ago · In the assessment of 12-month price targets, analysts unveil insights for Regeneron Pharmaceuticals, presenting an average target of $1069.69, a high estimate of $1229.00, and a low estimate of ...
Regeneron is a leading biotechnology company using the power of science to bring new medicines to patients in need. Explore Regeneron's global presence.
Monitor SARS-CoV-2 variants with Regeneron’s COVID-19 Dashboard. Refreshed daily with new genomes and associated patient metadata. Learn how Regeneron is actively working on testing existing medicines and developing new antibodies to combat the COVID-19 pandemic.
Mar 23, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalized patients (n=4,567). This definitive Phase 3 outcomes trial in high-risk non-hospitalized COVID-19 patients ("outpatients") met its primary endpoint, showing the ...
Jun 16, 2024 · Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation. May 23. Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO. May 20.
Jul 30, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail REGEN-COV™ (casirivimab and imdevimab). The authorization now includes post-exposure prophylaxis in people at high risk for progression ...
2 days ago · We are a leading science and technology company that delivers life-transforming medicines for serious diseases. Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in many FDA-approved medicines and numerous product candidates in a range of diseases, including blindness-causing eye diseases, severe ...
